Photos from Envato
Currently, TREG-based therapies have not been approved.
According to a report by Delveinsight, the regulatory T cell (Tregs) sectors in seven major markets (7mm) are expected to grow at a compound growth rate of more than 57% as of 2034.
As the company actively develops new regulatory T cell therapies to address different diseases such as lupus nephritis, atopic dermatitis, rheumatoid arthritis and psoriasis.
Currently, TREG-based therapies have not been approved. First approval is expected in the United States by 2026, which is expected to drive early market expansion.
7mm = US, Germany, France, Italy, Spain, UK and Japan.
Join the Healthcare Asia Magazine Community
Since you're here…
…You can promote your company with us and connect with your customers in a variety of ways. Our team can help you Dight and create advertising campaigns on print and digitally on this website and on print magazines.
We can also organize real-life or digital events for you and find thought leader speakers and industry leaders who can become your potential partners to attend. We also run a number of award programs that give you the opportunity to earn your achievements this year and you can join as a participant or sponsor.
Let us help you move your business forward with a good partnership!
